Fighting coronavirus with MSCs: an interview with Ross Macdonald

Written by RegMedNet
Asia and the rest of the world Cell therapy Clinical trials COVID-19 FDA Interviews MSCs Wound healing

Ross Macdonald (Cynata, Melbourne, Australia) discusses the coronavirus outbreak following the news that mesenchymal stem cells (MSCs) had been successfully tested in a clinical trial in China. Following the news that mesenchymal stem cells (MSCs) were utilized in the treatment of COVID-19 complications, we sat down with Ross Macdonald (Cynata, Melbourne, Australia) to discuss the situation. Due to the ever-evolving situation, we wish to clarify this interview was originally recorded on 15 March 2020. Can you introduce yourself and tell us a bit about your role, please? I'm Ross Macdonald, CEO of Cynata Therapeutics (Melbourne, Australia), which is a clinical-stage...

To view this content, please register now for access

It's completely free